Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study

Benjamin Rossi, View ORCID ProfileLee S. Nguyen, Philippe Zimmermann, Faiza Boucenna, Louis Dubret, Louise Baucher, Helene Guillot, Marie-Anne Bouldouyre, View ORCID ProfileYves Allenbach, Joe-Elie Salem, Paul Barsoum, Arezki Oufella, Helene Gros
doi: https://doi.org/10.1101/2020.06.06.20122341
Benjamin Rossi
1Department of Internal Medicine, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: benjamin.rossi@ght-gpne.fr
Lee S. Nguyen
2Research & innovation of CMC Ambroise Paré, 92200 Neuilly-sur-Seine, France
3Sorbonne Université, INSERM, Clinical Investigations Center Paris-Est, CIC-1901, AP.HP.6 Pitié-Salpétrière, 75013 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lee S. Nguyen
Philippe Zimmermann
4Department of pharmacy, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Faiza Boucenna
1Department of Internal Medicine, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Dubret
4Department of pharmacy, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise Baucher
1Department of Internal Medicine, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helene Guillot
1Department of Internal Medicine, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Anne Bouldouyre
1Department of Internal Medicine, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Allenbach
5Sorbonne Université, Department of Internal medicine and Clinical Immunology, AP.HP.6 Pitié-Salpétrière, 75013 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yves Allenbach
Joe-Elie Salem
3Sorbonne Université, INSERM, Clinical Investigations Center Paris-Est, CIC-1901, AP.HP.6 Pitié-Salpétrière, 75013 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Barsoum
6Department of cardiology, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arezki Oufella
4Department of pharmacy, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helene Gros
1Department of Internal Medicine, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Tocilizumab, a drug targeting interleukin-6 administrated in the right timeframe may be beneficial in coronavirus-disease-2019 (COVID-19). We aimed to assess its benefit, drawing from observations in compassionately treated patients.

Methods In a retrospective case-control study, treatment effect (tocilizumab 400mg, single-dose) was assessed using three statistical methods: propensity-score matching, Cox multivariable survival and inverse probability score weighting (IPSW) analyses. Were included all patients hospitalized with COVID-19, who presented severity criteria with SpO2≤96% despite O2-support ≥6L/min for more than 6 hours. Were excluded patients in critical care medicine department and those under invasive mechanical ventilation. Primary outcome was a composite of mortality and ventilation, with a maximum follow-up of 28 days.

Results 246 patients were included (106 treated by tocilizumab). They were 67.6 ±15.3 years-old, with 95 (38.5%) women. Delay between first symptoms and inclusion was 8.4 ±4.5 days. Overall, 105 (42.7%) patients presented the primary outcome, with 71 (28.9%) deaths during the 28-days follow-up. Propensity-score-matched 84 pairs of comparable patients. In the matched cohort (n = 168), tocilizumab was associated with fewer primary outcomes (hazard ratio (HR) = 0.49 (95% confidence interval (95CI) = 0.3–0.81), p-value = 0.005). These results were similar in the overall cohort (n = 246), with Cox multivariable analysis yielding a protective association between tocilizumab and primary outcome (adjusted HR = 0.26 (95CI = 0.135–0.51, p = 0.0001), confirmed by IPSW analysis (p<0.0001). Analyses on mortality with 28-days follow-up yielded similar results.

Conclusion In this retrospective study, tocilizumab single-dose was associated with improved survival without mechanical ventilation in patients with severe COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04366206

Funding Statement

none

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Regional ethics committee La Sorbonne CER-Sorbonne University (N CER-2020-27) gave us an institutional ethical agreement

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

data are not available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 09, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study
Benjamin Rossi, Lee S. Nguyen, Philippe Zimmermann, Faiza Boucenna, Louis Dubret, Louise Baucher, Helene Guillot, Marie-Anne Bouldouyre, Yves Allenbach, Joe-Elie Salem, Paul Barsoum, Arezki Oufella, Helene Gros
medRxiv 2020.06.06.20122341; doi: https://doi.org/10.1101/2020.06.06.20122341
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study
Benjamin Rossi, Lee S. Nguyen, Philippe Zimmermann, Faiza Boucenna, Louis Dubret, Louise Baucher, Helene Guillot, Marie-Anne Bouldouyre, Yves Allenbach, Joe-Elie Salem, Paul Barsoum, Arezki Oufella, Helene Gros
medRxiv 2020.06.06.20122341; doi: https://doi.org/10.1101/2020.06.06.20122341

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1746)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (651)
  • Epidemiology (10770)
  • Forensic Medicine (8)
  • Gastroenterology (582)
  • Genetic and Genomic Medicine (2930)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1917)
  • Health Policy (832)
  • Health Systems and Quality Improvement (741)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12495)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (319)
  • Neurology (2778)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (596)
  • Oncology (1451)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (254)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (378)
  • Pediatrics (863)
  • Pharmacology and Therapeutics (361)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2626)
  • Public and Global Health (5336)
  • Radiology and Imaging (1001)
  • Rehabilitation Medicine and Physical Therapy (592)
  • Respiratory Medicine (721)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (124)